Nektar Therapeutics released data from a study of its rezpegaldesleukin drug, establishing proof-of-concept in patients with severe to very severe alopecia areata, a hair-loss condition.

Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...

Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before ...

US biotech Nektar Therapeutics shares increased by 10% in pre-market trading following promising Phase IIb trial results.

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology ...

Nektar Therapeutics (NASDAQ:NKTR) reported results from its Phase 2b REZOLVE-AA study evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata, with the trial narrowly ...

Nektar (NKTR) announced topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational ...

People with alopecia areata who experience hair regrowth may also see improvements in their quality of life and mental health, according to a new study. A post hoc study conducted in adults with ...

Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...

Please provide your email address to receive an email when new articles are posted on . By week 152, 80% of patients who were withdrawn from baricitinib therapy lost their hair again vs. only 7% of ...

Credit: SUN Pharma. Leqselvi is supplied as a tablet containing 8mg of deuruxolitinib. Prior to initiating treatment with Leqselvi, certain evaluations and immunizations are recommended. Leqselvi ™ ...

Here are the top 5 most-viewed alopecia content in 2025.